Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase III, multi-center, open-label, parallel, 2-arm, randomized study to evaluate
the efficacy and safety of radotinib 300 mg Bis In Die(BID) versus imatinib 400 mg Quaque
Die(QD).
This study will be conducted in Chinese patients with newly diagnosed Ph+ Chronic Myelogenous
Leukemia(CML)-Chronic Phase(CP) who are previously untreated for Chronic Myelogenous
Leukemia(CML).